Aclaris Therapeutis (ACRS): Eskata and Pipeline Should Drive Shares Higher - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50 price target on Aclaris Therapeutis (NASDAQ: ACRS), saying Eskata ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
